A Phase 2 Placebo Controlled Study Evaluating the Platelet Response and Safety of Weekly Dosing with a Novel Thrombopoietic Protein (AMG531) in Thrombocytopenic Adult Patients (pts) with Immune Thrombocytopenic Purpura (ITP).

David J. Kuter(Harvard University), Janet L. Nichol(Amgen (United States)), Reggie Kelly(Amgen (United States)), Chien‐Feng Chen(Amgen (United States)), Louis M. Aledort(Icahn School of Medicine at Mount Sinai), James N. George(University of Oklahoma), James B. Bussel(Cornell University), Jorge J. Nieva(University of Southern California), George T. Conklin(Austin Diagnostic Clinic), Alan Lichtin(Cleveland Clinic), Roger M. Lyons(Hematology Oncology Associates)
Blood
November 16, 2004
10.1182/blood.v104.11.511.511
Cited by 17

Related Papers

Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group
|Blood|2008|2.6k
Updated international consensus report on the investigation and management of primary immune thrombocytopenia
|Blood Advances|2019|1.1k
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
|The Lancet|2008|862
Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis.
|PubMed|2001|803
Definitions in Hemophilia
|Thrombosis and Haemostasis|2001|772